Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a Finland-based clinical stage biopharmaceutical company, announced on Monday that it has named Marie-Louise Fjallskog, MD, PhD, as its new chief medical officer, effective immediately.

Dr Fjallskog has more than 30 years of experience in clinical oncology, translational research, and drug development. She has served as chief medical officer at Sensei Biotherapeutics. She has a PhD and an MD from Uppsala University, Sweden where she currently serves as an associate professor of Oncology.

In her new role, Dr Fjalskog is to join the company's management team and offer leadership and direction in accelerating the firm's clinical development programs. Her main concentration will be bexmarilimab, the company's wholly owned, novel precision cancer immunotherapy candidate, presently in development as a potential monotherapy in patients with solid tumours.